IP Library › Granted Patent US 10,814,020
Granted Patent B2
US 10,814,020 · App. 15/572,863 · Granted Oct 27, 2020

Targeted protein contrast agents, methods of making, and uses thereof

Inventors: Jenny Jie Yang (Atlanta, GA); Fan Pu (Atlanta, GA); Shenghui Xue (Atlanta, GA); Jingjuan Qiao (Atlanta, GA); Mani Salarian (Atlanta, GA); Shanshan Tan (Atlanta, GA)
Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
A61K49/143A61K49/126A61K49/16C01G99/006C07K14/76C07K2319/32C07K2319/33C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,814,020
App. No.
15/572,863
Granted
Oct 27, 2020
Kind
B2
Abstract

Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.

Claims (13)

1. A protein contrast agent comprising:

a parvalbumin polypeptide, wherein the parvalbumin polypeptide has the amino acid sequence according to SEQ ID NO. 10 or comprising SEQ ID NO.: 10, wherein the parvalbumin polypeptide contains a paramagnetic metal binding site consisting of one or more amino acid residues of SEQ ID NO. 10, and wherein the parvalbumin polypeptide comprising SEQ ID NO.: 10 further comprises a collagen-targeting moiety directly fused or indirectly linked via a flexible peptide linker to the C terminus of the parvalbumin polypeptide.

2. The protein contrast agent of claim 1 , further comprising a paramagnetic ion, wherein the paramagnetic ion is directly bound to at least one amino acid of the parvalbumin polypeptide.

3. The protein contrast agent of claim 2 , wherein the paramagnetic ion is Gd 3+ .

4. The protein contrast agent of claim 1 , wherein the protein contrast agent is PEGylated.

5. A pharmaceutical composition comprising:

a protein contrast agent according to claim 1 ; and

a pharmaceutically acceptable carrier.

6. The protein contrast agent of claim 1 , wherein the collagen-targeting moiety has an amino acid sequence selected from SEQ ID NOs.: 59-65.

7. A method of generating a magnetic resonance image of fibrosis or cancer in subject, the method comprising:

administering an amount of a protein contrast agent according to claim 1 or a

pharmaceutical formulation thereof to a subject; and

imaging at least a portion of the subject using magnetic resonance imaging.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2019
From: YANG, JENNY JIE; PU, FAN; XUE, SHENGHUI; QIAO, JINGJUAN; TAN, SHANSHAN; SALARIAN, MANI
To: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
Reel/Frame 047991/0559 →
Continuity (2)
Provisional Application 62159685 · May 11, 2015
Related Publication 20180280544A1 · Oct 4, 2018
Cited By (2)
US 12,491,268 US 12,708,677